Sign up USA
Proactive Investors - Run By Investors For Investors

Affimed teams up with Merck for cancer drug trial

The Phase 1b trial is expected to will be funded and conducted by Affimed, and it is expected to get underway in the first half of 2016.
Affimed teams up with Merck for cancer drug trial
Patient derived models showed up to 90% of a tumour could be eradicated.

Cancer drug developer Affimed N.V. (NASDAQ:AFMD) has struck a collaboration agreement with Merck which will involve a new drugs trial for patients with Hodgkin lymphoma.

Nasdaq quoted Affimed, which is headquartered in Germany, will fund and conduct the Phase 1b trial in which it will combine Merck's KEYTRUDA (pembrolizumab) drug, with Affimed's proprietary  candidate AFM13.

The trial will involve patients with Hodgkin lymphoma whose disease has relapsed or is refractory to chemotherapy. Its purpose will be to establish a dosing regimen, as well as assessing safety and efficacy.

It is expected that the study will begin in the first half of this year.

"AFM13, a first-in-class NK-cell engager, has shown an acceptable safety profile and preliminary antitumor activity in the first-in-human Phase 1 study,” said Dr Adi Hoess, Affimed chief executive.

“Additionally, preclinical studies indicate that a combination with an anti PD-1 therapy could act synergistically and represent an additional future treatment option for patients."

NK (or Natural Killer) cells are important in the activation of the innate immune system and the subsequent killing of tumor cells, Affimed explained in a statement.

The company also highlighted that in patient derived models at Stanford University AFM13, in combination with an anti-PD-1 antibody (Merck’s KEYTRUDA is an example of this kind of drug) demonstrated “impressive synergy” with up to 90% of the tumor eradicated.

Dr Eric Rubin, a vice president and therapeutic area head at Merck Research Laboratories,  meanwhile, said: "Evaluating the potential for innovative combination therapies through strategic collaborations in difficult-to-treat tumor types continues to be an important part of our clinical development program for KEYTRUDA.”

"In partnering with companies such as Affimed, we continue our efforts to bring forward new scientific breakthroughs for patients with Hodgkin lymphoma and the field of immuno-oncology overall."

View full INDU profile View Profile

US Market News Timeline

March 15 2018

Related Articles

March 15 2018
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment
picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.
researcher filling a vial
April 23 2018
2018 is shaping up to be a crucial year for the company's drug pipeline

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use